WHO ICTRP trial
Chemotherapy plus Toripalimab Augmented by Hypofractionated Radiotherapy as…
ChiCTR1900025796 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1900025796 |
|---|---|
| Public title | Chemotherapy plus Toripalimab Augmented by Hypofractionated Radiotherapy as First Line Treatment for Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
| Scientific title | A prospective, one-arm, single-center clinical study for chemotherapy plus Toripalimab augmented by hypofractionated radiotherapy as first line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) |
| Primary sponsor | Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck |
| Interventions | Treatment Group:Chemotherapy plus Toripalimab Augmented by Hypofractionated Radiotherapy |
| Registration date | Sep 8, 2019 |
| Target size | Treatment Group:36 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: